Health Canada Approves Moderna's mRNA-Based RSV Vaccine, mRESVIA
Key Insights
Health Canada has approved Moderna's mRESVIA vaccine for active immunization against lower respiratory tract disease caused by respiratory syncytial virus (search) (RSV) in adults aged 60 and older.
This approval marks the second Health Canada approval for Moderna, highlighting the potential of its mRNA platform to address significant public health challenges.
mRESVIA generated $10 million in sales during its first quarter of commercialization, having already gained approval in the US and Europe earlier this year.
Moderna's mRESVIA, a respiratory syncytial virus (search) (RSV) mRNA vaccine, has received approval from Health Canada for active immunization in adults 60 years and older, designed to prevent lower respiratory tract disease caused by RSV. This approval follows the vaccine's earlier authorization in the United States and Europe, marking a significant milestone for Moderna's mRNA platform.
The approval underscores the potential of mRNA technology in addressing public health challenges. According to Moderna CEO Stéphane Bancel, this approval highlights the company's commitment to leveraging mRNA technology to protect vulnerable populations and contribute to a healthier future for Canadians.
mRESVIA generated $10 million in sales in its first quarter of commercialization, indicating a strong initial uptake following its launch in other markets. The vaccine aims to address the significant burden of RSV-related lower respiratory tract disease in older adults, a population particularly vulnerable to severe outcomes.